SILO

Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic

Retrieved on: 
Wednesday, April 10, 2024
University, Hope, Administration, Columbia University, Research, SILO, Disease, Therapy, Patient, Prevalence, Pharmaceutical industry

SARASOTA, FL, April 10, 2024 (GLOBE NEWSWIRE) --  Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has exercised its option to license Alzheimer’s disease (AD) therapeutic SPC-14 from Columbia University, pursuant to a sponsored research and option agreement established in 2021. Under the terms of the license agreement currently in process, Silo will be granted an exclusive license to further develop, manufacture, and commercialize SPC-14 worldwide upon consummation of such agreement. The Company expects to finalize and enter into the exclusive license agreement in the first half of 2024.

Key Points: 
  • Under the terms of the license agreement currently in process, Silo will be granted an exclusive license to further develop, manufacture, and commercialize SPC-14 worldwide upon consummation of such agreement.
  • The Company expects to finalize and enter into the exclusive license agreement in the first half of 2024.
  • “Columbia University has discovered a therapeutic candidate that could bring relief and hope for Alzheimer’s patients and families,” said Eric Weisblum, CEO of Silo.
  • Rising prevalence of the disease in the expanding elderly population and advancements in neurological research are expected to drive market growth.

Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic

Retrieved on: 
Wednesday, March 20, 2024
Exercise, New Drug Application, Research, Anxiety, Columbia University, IND, SILO, Therapy, FDA, PTSD, Administration, Pharmaceutical industry

SARASOTA, FL, March 20, 2024 (GLOBE NEWSWIRE) --  Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has exercised its option to license SPC-15, a prophylactic treatment for stress-induced affective disorders including anxiety and PTSD, from Columbia University, pursuant to a sponsored research and option agreement established in 2021. Under the terms of the license agreement currently in process, Silo will be granted an exclusive license to further develop, manufacture, and commercialize SPC-15 worldwide. The Company expects to finalize and enter into the exclusive license agreement in the first half of 2024.

Key Points: 
  • Under the terms of the license agreement currently in process, Silo will be granted an exclusive license to further develop, manufacture, and commercialize SPC-15 worldwide.
  • The Company expects to finalize and enter into the exclusive license agreement in the first half of 2024.
  • In contrast, SPC-15’s differentiated method of action is designed to increase stress resilience in high-risk populations.
  • Silo has identified clinical development of lead asset SPC-15 as the Company’s top strategic priority in 2024.

Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain

Retrieved on: 
Monday, March 18, 2024
Combination, Fibromyalgia, Patent, Chronic pain, SILO, Ketamine, Therapy, Administration, Medical device

SARASOTA, FL, March 18, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has filed a provisional patent application titled ‘Methods and Combinations for Managing Pain’ with the United States Patent and Trademark Office (USPTO).

Key Points: 
  • The patent application includes protection for the Company’s SP-26 implantable drug delivery system for a novel time-released, dose-controlled formulation of ketamine, initially targeted for fibromyalgia.
  • Silo believes that implantable drug delivery may be well-suited for chronic pain management.
  • “Our SP-26 implant technology is designed to deliver a steady, low dose of ketamine for sustained relief of chronic pain,” said Eric Weisblum, CEO of Silo.
  • If approved, SP-26 could be the first at-home approved ketamine based therapeutic.”
    The next tests of the SP-26 ketamine implant will measure drug dissolution and time-release action.

Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD

Retrieved on: 
Wednesday, February 28, 2024
Therapy, Anxiety, Toxicology, New Drug Application, Data analysis, Absorption, FDA, GLP, Safety, Administration, Post-traumatic stress disorder, SILO, PTSD, IND, Pharmaceutical industry

SARASOTA, FL, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced positive results from its non-GLP small animal dose-ranging study of SPC-15, an intranasal prophylactic treatment for anxiety and post-traumatic stress disorder (PTSD).

Key Points: 
  • The purpose of the non-GLP small animal study was to identify the maximum tolerated intranasal dose of the drug pharmacokinetic and determine the therapeutically relevant dose range to be studied in clinical trials.
  • Data analysis demonstrated rapid absorption of SPC-15 with good exposure over a 24-hour period, suggesting a once-per-day human intranasal dosing regimen would be optimal.
  • “Non-GLP and GLP toxicology and safety pharmacology studies are required steps before seeking approval for our first-in-human clinical-stage trials of SPC-15,” said Eric Weisblum, CEO of Silo.
  • This is an exciting step forward for our Company as we advance our lead therapeutic, SPC-15.”

Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery

Retrieved on: 
Wednesday, February 14, 2024
IDDS, Therapy, Fibromyalgia, Blood, Ketamine, Administration, Chronic pain, HCL, SILO, Medical device

SARASOTA, FL, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today provided a positive update on SP-26, its novel time-released, dose-controlled formulation of ketamine initially targeted for fibromyalgia. A pre-clinical research study is underway involving analytical testing services and small batch proof-of-concept extrusion trials to determine drug release and stability.

Key Points: 
  • A pre-clinical research study is underway involving analytical testing services and small batch proof-of-concept extrusion trials to determine drug release and stability.
  • In recent testing, SP-26 polymer implants were blended with ketamine hydrochloride (ketamine HCL) in two loadings, 20% and 40%.
  • “Implantable drug delivery systems like SP-26 may provide sustained drug delivery for prolonged periods of time, which is critical for the treatment of chronic pain conditions,” said Eric Weisblum, CEO of Silo.
  • Silo believes that implantable drug delivery systems (IDDS) can offer a superior delivery alternative for sustained relief from chronic pain.

Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology

Retrieved on: 
Thursday, February 1, 2024
Traffic barrier, PTSD, Multiple sclerosis, Inflammation, Fibromyalgia, Chronic pain, Research, Plasma protein binding, Therapy, SILO, Neurology, IND, New Drug Application, UMB, Central nervous system, FDA, Columbia University, Ketamine, GLP, Food, Mental health, CNS, Social media, Post-traumatic stress disorder, Administration, University, Pharmaceutical industry

SARASOTA, FL, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced updates for its strategic 2024 focus for its clinical pipeline. The Company is advancing a diversified portfolio of four drugs targeting three health areas: mental health, chronic pain, and neurology.

Key Points: 
  • The Company is advancing a diversified portfolio of four drugs targeting three health areas: mental health, chronic pain, and neurology.
  • A dose-ranging non GLP study of SPC-15 is in progress, with a final validation report expected in the first half of 2024.
  • As a self-administered treatment, SP-26 holds the potential to be the first at-home ketamine treatment approved for chronic pain management.
  • Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases.

Silo Pharma Announces Positive Results in Alzheimer’s Disease Study

Retrieved on: 
Wednesday, January 24, 2024
Patient, Female, Mouse, Administration, Anxiety, SILO, Therapy, Columbia University, Trial of the century, Pharmaceutical industry

SARASOTA, FL, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a biopharmaceutical company developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that its Alzheimer’s disease therapeutic SPC-14 showed positive efficacy in small animals.

Key Points: 
  • Preclinical study shows SPC-14’s effectiveness against LH (luteinizing hormone) stress, helplessness, and anxiety.
  • SARASOTA, FL, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a biopharmaceutical company developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that its Alzheimer’s disease therapeutic SPC-14 showed positive efficacy in small animals.
  • Data from a study conducted at Columbia University in collaboration with Silo Pharma showed that SPC-14 was effective against LH stress in attenuating learned helplessness, perseverative behavior, and hyponeophagia (a measure of anxiety).
  • We look forward to updating our shareholders on the next steps and data needed to advance SPC-14 to a clinical study,” stated Eric Weisblum, Chief Executive Officer of Silo Pharma.

Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD

Retrieved on: 
Thursday, January 4, 2024
IND, FDA, SILO, Columbia University, Investigational New Drug, GLP, PTSD, Animal, Post-traumatic stress disorder, Toxicity, Safety, Therapy, Pharmaceutical industry

ENGLEWOOD CLIFFS, NJ, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today provided an update on its previously announced dose-ranging study of SPC-15, a targeted prophylactic treatment for post-traumatic stress disorder (PTSD). The purpose of the study is to identify the maximum tolerated intranasal dose of the drug and pharmacokinetic in small animals to determine the therapeutically relevant dose range with the goal of bringing us closer to human trials.

Key Points: 
  • The purpose of the study is to identify the maximum tolerated intranasal dose of the drug and pharmacokinetic in small animals to determine the therapeutically relevant dose range with the goal of bringing us closer to human trials.
  • The six- to eight-week non-GLP study includes single ascending dose evaluation (phase 1) and a 7-day repeat intranasal dose toxicity and pharmacokinetic study.
  • In the first phase of the study, all of the animals appeared to tolerate the intranasal dosing procedure well, with minimal struggling and no sneezing observed.
  • Eric Weisblum, Chief Executive Officer of Silo Pharma, commented “There have been no adverse clinical observations reported to date for this study, which began in late November 2023 and will conclude in first quarter 2024.

Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia

Retrieved on: 
Thursday, December 28, 2023
DEA, Silo, Ketamine, Chronic pain, Therapy, SILO, Fibromyalgia

SARASOTA, FL, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced an update on its dosage and time-release ketamine-loaded implant, designated as SP-26, which is being developed as a potential at-home pain relief treatment for fibromyalgia and other chronic pain conditions. In collaboration with Sever Pharma Solutions, Silo’s contract development and manufacturing partner, SP-26 is advancing through analytical testing and small batch pre-clinical proof of concept extrusion trials to determine drug release and stability.

Key Points: 
  • In collaboration with Sever Pharma Solutions, Silo’s contract development and manufacturing partner, SP-26 is advancing through analytical testing and small batch pre-clinical proof of concept extrusion trials to determine drug release and stability.
  • Silo intends to pursue the FDA’s streamlined 505(b)(2) pathway for approval of SP-26.
  • Eric Weisblum, Chief Executive Officer of Silo Pharma, commented “Many chronic pain sufferers are seeking a non-opioid treatment that offers relief.
  • Based on findings to date, we believe SP-26 has the potential to be the first at-home approved ketamine treatment for chronic pain including fibromyalgia.”

Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD

Retrieved on: 
Tuesday, November 21, 2023
Research, Patient safety, Nose, SILO, Brain, Anxiety, PTSD, Post-traumatic stress disorder, Nasal cavity, Silicon, Therapy, Area studies, Argyreia nervosa, Pharmaceutical industry

ENGLEWOOD CLIFFS, NJ, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced a new exclusive license agreement with medical technology manufacturer Medspray Pharma BV for its proprietary patented soft mist nasal spray technology, the delivery mechanism selected for Silo’s intranasal therapeutic drug SPC-15.

Key Points: 
  • “We began a collaboration with Medspray earlier this year for feasibility studies evaluating its patented technology as a delivery mechanism for our intranasal therapeutic drug SPC-15.
  • Based on successful outcomes from these studies, we have selected Medspray’s Spray Technology for our formulation,” said Eric Weisblum, Chief Executive Officer of Silo Pharma.
  • “As part of our manufacturing and sales contract, we have obtained exclusive rights to its spray mist technology for use with multiple indications including post-traumatic stress disorder (PTSD) and anxiety, as well as Alzheimer’s disease and anorexia.
  • The drug dispersion through the nose to brain has been designed to optimize patient safety and therapeutic delivery.